彭布罗利珠单抗
医学
肝细胞癌
单克隆抗体
肿瘤微环境
癌症研究
磷脂酰丝氨酸
作者
D. Hsiehchen,R. Kainthla,Hao Zhu,A. Jones,Muhammad Shaalan Beg
标识
DOI:10.1016/j.annonc.2021.08.159
摘要
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and is responsible for more than 500,000 deaths annually. Bavi, a monoclonal antibody designed to inhibit the immunosuppressive effects of phosphatidylserine through interaction with TIM and TAM receptor family members in the tumor microenvironment (TME), is being evaluated in combination with pembro, a monoclonal antibody designed to inhibit Programmed cell death protein 1 (PD-1), in patients with advanced HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI